Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
In order to assess the role of CaT1 in generating endogenous store-operated Ca(2+) current (I(SOC)) in the lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of I(SOC).
|
12584203 |
2003 |
Malignant neoplasm of prostate
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Finally, we found CaT1 protein to be present at elevated levels in comparison with normal tissues in a series of prostate, breast, thyroid, colon, and ovarian carcinomas, consistent with previous reports of up-regulation of CaT1 mRNA in prostate cancer tissues.
|
12480925 |
2002 |
Malignant neoplasm of prostate
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
CaT1 expression correlates with tumor grade in prostate cancer.
|
11401523 |
2001 |
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
CTD_human |
CaT1 expression correlates with tumor grade in prostate cancer.
|
11401523 |
2001 |
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
CaT1 expression correlates with tumor grade in prostate cancer.
|
11401523 |
2001 |
Cardiovascular Diseases
|
0.110 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Cardiovascular Diseases
|
0.110 |
GeneticVariation
|
group |
BEFREE |
The incidence of CVD has revealed a statistically significant dose response with the lack of a latent period and with the average ERR Gy = 0.47, 95% CI = 0.31, 0.63, p < 0.001.
|
28542008 |
2017 |
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ethnic association study of blood pressure determinants in over 750,000 individuals.
|
30578418 |
2019 |
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation.
|
27841878 |
2017 |
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation.
|
27841878 |
2017 |
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
The results of the present study indicate that miR-145 functions as a key mediator in the pathogenesis of hypertension via targeting SLC7A1, which suggests that miR-145 is a potential target for the treatment of hypertension.
|
29434681 |
2018 |
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Contribution of SLC7A1 genetic variant to hypertension, the TAMRISK study.
|
23841815 |
2013 |
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Mechanistic insights into the link between a polymorphism of the 3'UTR of the SLC7A1 gene and hypertension.
|
19067360 |
2009 |
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction.
|
17325243 |
2007 |
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
LHGDN |
Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction.
|
17325243 |
2007 |
Essential Hypertension
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The rs41318021 polymorphism in the SLC7A1 gene was not associated with essential hypertension in 50-year-old subjects.
|
23841815 |
2013 |
Essential Hypertension
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We previously identified the polymorphism ss52051869 in the 3'UTR of human SLC7A1, and demonstrated that it might participate in the apparent link between altered endothelial function, decreased L-arginine and nitric oxide (NO) metabolism, and a genetic predisposition to essential hypertension.
|
19067360 |
2009 |
Essential Hypertension
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In vivo and in vitro measures of L-arginine transport were substantially reduced in the essential hypertension and positive family history groups compared with the negative family history group; however, no difference was detected in peripheral blood mononuclear cell mRNA or protein expression levels for the cationic amino acid transporter CAT-1.
|
15569830 |
2004 |
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In order to assess the role of CaT1 in generating endogenous store-operated Ca(2+) current (I(SOC)) in the lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of I(SOC).
|
12584203 |
2003 |
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Finally, we found CaT1 protein to be present at elevated levels in comparison with normal tissues in a series of prostate, breast, thyroid, colon, and ovarian carcinomas, consistent with previous reports of up-regulation of CaT1 mRNA in prostate cancer tissues.
|
12480925 |
2002 |
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These findings are the first to implicate a Ca(2+) channel in PCa progression and suggest that CaT1 may be a novel target for therapy.
|
11401523 |
2001 |
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggested that CAT1 promotes the tumorigenesis and progression of GC by negatively regulating miR-219-1.
|
31478245 |
2019 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, these results suggested that CAT1 promotes the tumorigenesis and progression of GC by negatively regulating miR-219-1.
|
31478245 |
2019 |